NCT04491721Enrolling by invitation
Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL
Long-term Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL
Source: ClinicalTrials.gov · Last updated 29 Jul 2020 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The main objective of this study is to observe the overall survival of Rituximab Biosimilar HLX01 and MabThera in Combination With CHOP, in previously untreated subjects with CD20+ DLBCL. The secondary objective of this study is to observe the progression-free survival of Rituximab Biosimilar HLX01 and MabThera in Combination With CHOP, in previously untreated subjects with CD20+ DLBCL.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 407 (estimated)
- First submitted
- 25 Jul 2020
- Start date
- Jul 2020
- Primary completion date
- Jun 2027
- Lead sponsor
- Chinese Academy of Medical Sciences
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT04491721
What you commit to
- Study type: Observational
- Planned participants: 407
- From Jul 2020 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- ①Subjects died; ②Subjects are unwilling to participate in follow-up study; ③ the investigator judges that the subject is not suitable for participating the study.
Who the study is looking for
- Subjects who have participated in Phase III study（NCT02787239）.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.